MX2019001313A - Composiciones farmaceuticas. - Google Patents

Composiciones farmaceuticas.

Info

Publication number
MX2019001313A
MX2019001313A MX2019001313A MX2019001313A MX2019001313A MX 2019001313 A MX2019001313 A MX 2019001313A MX 2019001313 A MX2019001313 A MX 2019001313A MX 2019001313 A MX2019001313 A MX 2019001313A MX 2019001313 A MX2019001313 A MX 2019001313A
Authority
MX
Mexico
Prior art keywords
powder compositions
pharmaceutical powder
intranasal pharmaceutical
compositions
intranasal
Prior art date
Application number
MX2019001313A
Other languages
English (en)
Spanish (es)
Inventor
Haruta Shunji
Original Assignee
Shin Nippon Biomedical Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shin Nippon Biomedical Laboratories Ltd filed Critical Shin Nippon Biomedical Laboratories Ltd
Publication of MX2019001313A publication Critical patent/MX2019001313A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A61K31/515—Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Inorganic Chemistry (AREA)
  • Anesthesiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2019001313A 2016-08-05 2017-08-04 Composiciones farmaceuticas. MX2019001313A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662371298P 2016-08-05 2016-08-05
PCT/IB2017/001121 WO2018025089A2 (en) 2016-08-05 2017-08-04 Pharmaceutical compositions

Publications (1)

Publication Number Publication Date
MX2019001313A true MX2019001313A (es) 2019-09-26

Family

ID=60084012

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019001313A MX2019001313A (es) 2016-08-05 2017-08-04 Composiciones farmaceuticas.

Country Status (9)

Country Link
US (2) US10792253B2 (enExample)
EP (1) EP3493789A2 (enExample)
JP (2) JP2019527703A (enExample)
KR (1) KR102489453B1 (enExample)
CN (1) CN109640947A (enExample)
AU (1) AU2017307306B2 (enExample)
CA (1) CA3030359A1 (enExample)
MX (1) MX2019001313A (enExample)
WO (1) WO2018025089A2 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015044782A2 (en) 2013-09-24 2015-04-02 Shin Nippon Biomedical Laboratories, Ltd. Intranasal dhe for the treatment of headache
US20200297734A1 (en) 2015-06-19 2020-09-24 Melt Pharmaceuticals, Inc. Pharmaceutical compositions and methods for anesthesiological applications
US20190142841A1 (en) * 2015-06-19 2019-05-16 Harrow Health, Inc. Pharmaceutical compositions and methods for anesthesiological applications
NZ741171A (en) 2015-09-10 2022-01-28 Impel Neuropharma Inc In-line nasal delivery device
WO2018025089A2 (en) 2016-08-05 2018-02-08 Shin Nippon Biomedical Laboratories, Ltd. Pharmaceutical compositions
PL3505157T3 (pl) 2017-12-29 2022-04-11 Celon Pharma S.A. Kompozycja ketaminy w postaci suchego proszku do podawania dopłucnego w leczeniu depresji opornej na leczenie
JP7317020B2 (ja) 2018-01-05 2023-07-28 インペル ファーマシューティカルズ インコーポレイテッド 精密嗅覚デバイスによるジヒドロエルゴタミンの鼻腔内送達
EP3893877A4 (en) * 2018-12-11 2022-09-14 Satsuma Pharmaceuticals, Inc. COMPOSITIONS, DEVICES AND METHODS FOR TREATMENT OR PREVENTION OF HEADACHE
GB2581431A (en) * 2018-12-11 2020-08-19 Satsuma Pharmaceuticals Inc Compositions, devices, and methods for treating or preventing headaches
CN111346078B (zh) * 2018-12-21 2022-06-10 宜昌人福药业有限责任公司 一种他喷他多或其药学上可接受的盐经鼻粘膜给药的药物组合物及其制备方法和应用
EP3970696A4 (en) 2019-05-16 2023-03-01 Shin Nippon Biomedical Laboratories, Ltd. POWDER PREPARATION FOR TRANSNASAL ADMINISTRATION AND MANUFACTURING METHOD THEREOF
SG11202113182XA (en) * 2019-05-28 2021-12-30 The Charlotte Mecklenburg Hospital Authority D/B/A Atrium Health Compositions and methods of making ribitol
WO2021158957A1 (en) 2020-02-05 2021-08-12 Summit Biosciences Inc. Drug products for intranasal administration and uses thereof
US11400045B2 (en) * 2020-03-16 2022-08-02 Nasus Pharma Ltd. Treatment with powdered intranasal epinephrine
AU2021236662A1 (en) * 2020-03-18 2022-11-10 Cara Therapeutics, Inc. Oligosaccharide formulations of kappa opioid receptor agonists
SMT202200411T1 (it) 2020-05-18 2022-11-18 Orexo Ab Nuova composizione farmaceutica per il rilascio controllato di farmaci
KR102563646B1 (ko) * 2021-04-06 2023-08-07 (주)메디코어 비강 세정용 분말 조성물의 제조방법 및 그에 따라 제조된 비강 세정용 분말 조성물
WO2022224030A1 (en) * 2021-04-20 2022-10-27 Sava Healthcare Ltd Dry powder inhalation (dpi) formulation
GB202117016D0 (en) 2021-11-25 2022-01-12 Orexo Ab New pharmaceutical device
AU2022395920A1 (en) 2021-11-25 2024-05-30 Orexo Ab Pharmaceutical composition comprising adrenaline
EP4486448A1 (en) 2022-03-04 2025-01-08 Reset Pharmaceuticals, Inc. Co-crystals or salts comprising psilocin
WO2024073588A1 (en) * 2022-09-28 2024-04-04 Board Of Regents, The University Of Texas System Respiratory dry powder delivery
CN115737568A (zh) * 2022-11-24 2023-03-07 东南大学 一种利培酮鼻用粉雾剂及其制备方法
AU2023400620A1 (en) * 2022-12-01 2025-06-12 Pinata Holdings Inc. Inhalable hormone receptor agonist formulations
CN117003689A (zh) * 2023-09-28 2023-11-07 成都瑞尔医药科技有限公司 一种碘解磷定的晶型及其制备方法
WO2025101272A1 (en) * 2023-11-11 2025-05-15 Css Pharma L.L.C. Pharmaceutical composition for the acute treatment of migraine and other forms of headache

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5169849A (en) * 1982-02-01 1992-12-08 Sandoz Ltd. Nasal pharmaceutical compositions
SE9604486D0 (sv) * 1996-12-05 1996-12-05 Astra Ab Novel formulation
EP1108423B1 (en) * 1998-08-26 2005-03-30 Teijin Limited Powdery pernasal compositions
US20030198669A1 (en) * 2001-07-05 2003-10-23 R.T. Alamo Ventures I, Llc Compositions and methods for rapid dissolving formulations of dihydroergotamine and caffeine for the treatment of migraine
GB0304636D0 (en) * 2003-02-28 2003-04-02 Britannia Pharmaceuticals Ltd Pharmaceutical composition for nasal delivery
WO2006016530A1 (ja) * 2004-08-10 2006-02-16 Translational Research, Ltd. 速効性でかつ高い吸収性を可能とする経鼻投与用組成物
WO2006040596A2 (en) * 2004-10-11 2006-04-20 Nasaleze Ppm Limited Compositions for intranasal administration
US20080096924A1 (en) * 2004-12-17 2008-04-24 Ono Pharmaceutical Co., Ltd. Amorphous Composition
ES2652415T3 (es) * 2006-12-26 2018-02-02 Shin Nippon Biomedical Laboratories, Ltd. Preparación para aplicación transnasal
US20110077272A1 (en) * 2008-02-01 2011-03-31 Vectura Limited Pulmonary formulations of triptans
CA2734646C (en) 2008-08-20 2016-06-28 James W. Mcginity Hot-melt extrusion of modified release multi-particulates
AU2010239161B2 (en) 2009-04-24 2014-10-09 Iceutica Pty Ltd Production of encapsulated nanoparticles at commercial scale
US20100291221A1 (en) * 2009-05-15 2010-11-18 Robert Owen Cook Method of administering dose-sparing amounts of formoterol fumarate-budesonide combination particles by inhalation
GB2472327B (en) 2009-07-31 2013-03-13 Shin Nippon Biomedical Lab Ltd Intranasal granisetron and nasal applicator
WO2012105236A1 (en) 2011-01-31 2012-08-09 Shin Nippon Biomedical Laboratories, Ltd. Intranasal delivery devices
EP2601973A1 (en) 2011-12-09 2013-06-12 Laboratoires SMB SA Dry powder formulation of azole derivative for inhalation
AU2014226192B2 (en) 2013-03-04 2018-07-26 Besins Healthcare Luxembourg Sarl Dry pharmaceutical compositions comprising active agent nanoparticles bound to carrier particles
WO2015044782A2 (en) 2013-09-24 2015-04-02 Shin Nippon Biomedical Laboratories, Ltd. Intranasal dhe for the treatment of headache
RU2570092C2 (ru) 2013-09-30 2015-12-10 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Петрозаводский государственный университет" Способ выявления различий структурного состояния целлюлозы
WO2018025089A2 (en) 2016-08-05 2018-02-08 Shin Nippon Biomedical Laboratories, Ltd. Pharmaceutical compositions

Also Published As

Publication number Publication date
RU2019105698A3 (enExample) 2020-11-18
JP7366178B2 (ja) 2023-10-20
CA3030359A1 (en) 2018-02-08
CN109640947A (zh) 2019-04-16
US20180036247A1 (en) 2018-02-08
US10792253B2 (en) 2020-10-06
AU2017307306A1 (en) 2019-01-17
RU2019105698A (ru) 2020-09-08
KR102489453B1 (ko) 2023-01-16
BR112019002371A2 (pt) 2019-06-04
KR20190038589A (ko) 2019-04-08
WO2018025089A2 (en) 2018-02-08
WO2018025089A3 (en) 2018-03-15
EP3493789A2 (en) 2019-06-12
US20200397702A1 (en) 2020-12-24
AU2017307306B2 (en) 2022-06-30
JP2022078268A (ja) 2022-05-24
US11872314B2 (en) 2024-01-16
JP2019527703A (ja) 2019-10-03

Similar Documents

Publication Publication Date Title
WO2018025089A3 (en) Intranasal pharmaceutical powder compositions
PL3668937T3 (pl) Kompozycje i zastosowania Z-1-chloro-2,3,3,3-tetrafluoroprop-1-enu
MX2023011657A (es) Composiciones que comprenden curones y usos de los mismos.
MX391052B (es) Represores de htt y usos de estos.
MY191581A (en) Anti-pd-1 antibodies
EP4279071A3 (en) Novel cannabinoid formulations
MX2022015755A (es) Profarmacos de hormona paratiroidea (pth).
IL262497A (en) Anti-il-33 antibodies, compositions, methods and uses thereof
PH12018500950A1 (en) Subcutaneous formulations of anti-cd38 antibodies and their uses
MX2020005213A (es) Inhibidores de proteina cinasa 2 activada por proteina cinasa activada por mitogeno (mk2) y sus usos.
GEP20217239B (en) Pharmaceutical composition
MX2021010418A (es) Composiciones que comprenden una caseína y métodos para producir las mismas.
MX2018016038A (es) Compuestos y metodos para modular la funcion del acido ribonucleico (arn).
PH12019501872A1 (en) Anti-tryptase antibodies, compositions thereof, and uses thereof
MX2019010984A (es) Composiciones de sintecina y metodos de uso.
MX2018004674A (es) Moduladores de interacción de sestrina-gator2 y sus usos.
MX2019002057A (es) Formas solidas de mesilato de cenicriviroc y procesos para elaborar formas sólidas de mesilato de cenicriviroc.
MX2018008424A (es) Compuestos antiproliferativos y sus composiciones farmaceuticas y usos.
MX2019005855A (es) Formulaciones que se pueden pulverizar.
MX2018000395A (es) Proteinas y composiciones inmunizantes que contienen proteinas de klebsiella y metodos de uso.
GEP20217240B (en) Pharmaceutical composition
EP3197621A4 (en) Titanium-based compositions, methods of manufacture and uses thereof
MX2017008390A (es) Uretanos funcionalizados con alcoxisilano y funcionalizados con alofanato.
MX2019000246A (es) Formas en estado solido del dimesilato de palbociclib.
MY192958A (en) Mixed decyl mercaptans compositions and methods of making same